PortfoliosLab logo
TG Therapeutics, Inc. (TGTX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US88322Q1085

CUSIP

88322Q108

IPO Date

Dec 14, 1995

Highlights

Market Cap

$5.45B

EPS (TTM)

$0.25

PE Ratio

137.44

Total Revenue (TTM)

$386.39M

Gross Profit (TTM)

$337.73M

EBITDA (TTM)

$66.40M

Year Range

$15.16 - $46.48

Target Price

$41.20

Short %

19.04%

Short Ratio

8.05

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

TG Therapeutics, Inc. (TGTX) returned 14.15% year-to-date (YTD) and 108.50% over the past 12 months. Over the past 10 years, TGTX returned 7.97% annually, underperforming the S&P 500 benchmark at 10.87%.


TGTX

YTD

14.15%

1M

-10.33%

6M

16.32%

1Y

108.50%

5Y*

12.87%

10Y*

7.97%

^GSPC (Benchmark)

YTD

1.30%

1M

12.79%

6M

1.49%

1Y

12.35%

5Y*

15.37%

10Y*

10.87%

*Annualized

Monthly Returns

The table below presents the monthly returns of TGTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20255.32%-5.08%31.04%15.42%-24.50%14.15%
2024-4.92%6.03%-11.67%-10.19%19.33%9.14%11.07%18.88%-0.43%7.14%38.87%-13.51%76.23%
202328.74%5.19%-6.12%65.09%7.25%-6.72%-16.71%-49.40%-20.15%-7.54%65.72%33.33%44.38%
2022-39.11%-14.69%-3.65%-27.02%-36.31%-3.85%40.94%19.03%-16.97%-1.69%51.55%34.13%-37.74%
2021-7.21%-9.32%10.12%-7.24%-22.01%11.24%-9.80%-22.64%22.94%-6.19%-51.31%25.00%-63.48%
202028.02%-11.68%-21.59%19.51%58.59%4.45%0.51%26.69%7.88%-5.57%16.11%77.30%368.65%
20190.00%65.85%18.24%-1.12%-21.13%37.96%-13.41%-17.09%-9.58%21.64%19.91%35.53%170.73%
201840.24%21.74%1.43%1.06%-6.62%-1.87%-10.65%8.09%-55.91%-18.75%10.77%-18.65%-50.00%
20173.23%18.75%104.39%-5.15%1.81%-10.67%14.43%10.43%-6.69%-31.22%5.52%-4.65%76.34%
2016-31.52%1.96%2.28%6.92%-17.45%-19.41%-2.48%7.45%21.89%-30.88%7.48%-19.13%-61.02%
2015-10.10%1.90%6.69%-9.82%12.75%5.40%5.18%-29.63%-17.92%22.72%6.55%-9.48%-24.68%
201453.85%10.00%4.55%-22.75%22.51%43.80%-15.76%7.21%25.83%3.00%35.76%6.17%306.15%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 88, TGTX is among the top 12% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of TGTX is 8888
Overall Rank
The Sharpe Ratio Rank of TGTX is 9292
Sharpe Ratio Rank
The Sortino Ratio Rank of TGTX is 8888
Sortino Ratio Rank
The Omega Ratio Rank of TGTX is 8585
Omega Ratio Rank
The Calmar Ratio Rank of TGTX is 8282
Calmar Ratio Rank
The Martin Ratio Rank of TGTX is 9494
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for TG Therapeutics, Inc. (TGTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

TG Therapeutics, Inc. Sharpe ratios as of May 19, 2025 (values are recalculated daily):

  • 1-Year: 1.55
  • 5-Year: 0.13
  • 10-Year: 0.09
  • All Time: -0.11

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of TG Therapeutics, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


TG Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the TG Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the TG Therapeutics, Inc. was 100.00%, occurring on Dec 29, 2011. The portfolio has not yet recovered.

The current TG Therapeutics, Inc. drawdown is 99.98%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Oct 23, 19973241Dec 29, 2011
-51.9%Feb 29, 1996244Apr 11, 1997110Oct 13, 1997354
-13.7%Feb 9, 19967Feb 20, 19962Feb 22, 19969
-13.21%Jan 15, 19963Jan 17, 199612Feb 2, 199615
-10.2%Dec 29, 19951Dec 29, 19956Jan 10, 19967

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of TG Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of TG Therapeutics, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -82.8%.


-0.500.000.5020212022202320242025
0.03
0.17
Actual
Estimate

Valuation

The Valuation section provides an overview of how TG Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for TGTX, comparing it with other companies in the Biotechnology industry. Currently, TGTX has a P/E ratio of 137.4. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for TGTX compared to other companies in the Biotechnology industry. TGTX currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for TGTX relative to other companies in the Biotechnology industry. Currently, TGTX has a P/S ratio of 14.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for TGTX in comparison with other companies in the Biotechnology industry. Currently, TGTX has a P/B value of 23.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items